

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Blonanserin (oral dosage form)

March 17, 2026

Therapeutic category

Psychotropic agents

Non-proprietary name

Blonanserin (oral dosage form)

Safety measure

PRECAUTIONS should be revised.

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.
 This English version is intended to be a reference material to provide convenience for users.
 In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revised language is underlined.

Current			Revision		
<p>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)</p> <p>Patients receiving the following drugs: Itraconazole, voriconazole, miconazole (oral dosage form, oral preparation, injectable dosage forms), fluconazole, fosfluconazole, posaconazole, preparations containing ritonavir, darunavir, atazanavir, fosamprenavir, ensitrelvir, preparations containing cobicistat, lonafarnib</p>			<p>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)</p> <p>Patients receiving the following drugs: Itraconazole, voriconazole, miconazole (oral dosage form, oral preparation, injectable dosage forms), fluconazole, fosfluconazole, posaconazole, preparations containing ritonavir, darunavir, atazanavir, fosamprenavir, ensitrelvir, preparations containing cobicistat, lonafarnib, <u>ceritinib</u></p>		
<p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration (Do not co-administer with the following.)</p>			<p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration (Do not co-administer with the following.)</p>		
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors
<p>Drugs that strongly inhibit CYP3A4</p> <p>Itraconazole Voriconazole Miconazole (oral dosage form, oral preparation, injectable dosage forms) Fluconazole Fosfluconazole Posaconazole</p>	<p>The blood concentration of this drug may increase, and the effects may be enhanced.</p>	<p>Oral clearance may decrease since these drugs inhibit CYP3A4, the major metabolic enzyme of this drug. It has been reported overseas that the</p>	<p>Drugs that strongly inhibit CYP3A4</p> <p>Itraconazole Voriconazole Miconazole (oral dosage form, oral preparation, injectable dosage forms) Fluconazole Fosfluconazole Posaconazole</p>	<p>The blood concentration of this drug may increase, and the effects may be enhanced.</p>	<p>Oral clearance may decrease since these drugs inhibit CYP3A4, the major metabolic enzyme of this drug. It has been reported overseas that the</p>

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Preparations containing ritonavir Darunavir Atazanavir Fosamprenavir Ensitrelvir Preparations containing cobicistat Lonafarnib		AUC and Cmax of this drug increased 17-fold and 13-fold, respectively, when co- administered with ketoconazole (oral dosage form; not marketed in Japan).	Preparations containing ritonavir Darunavir Atazanavir Fosamprenavir Ensitrelvir Preparations containing cobicistat Lonafarnib <u>Ceritinib</u>		AUC and Cmax of this drug increased 17-fold and 13-fold, respectively, when co- administered with ketoconazole (oral dosage form; not marketed in Japan).
--	--	--	--	--	--